SFE Investment Counsel’s Novavax NVAX Stock Holding History

SFE Investment Counsel’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-500	Closed	-$6K	–	116
2019 Q1	$6K	Hold	500	–	–	﹤0.01%	116
2018 Q4	$18K	Buy	+500	New	+$19.4K	0.01%	119

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SFE Investment Counsel's NVAX Position: Q2 2019 in Review

SFE Investment Counsel sold out of Novavax (NVAX) in Q2 2019, closing a stake of 500 shares — an estimated $6K sold.

SFE Investment Counsel first reported a position in NVAX in Q4 2018 and held it in 2 quarters. The position peaked at $18K in Q4 2018. 81 funds tracked by Wall St. Rank hold NVAX as of Q2 2019.

SFE Investment Counsel reported no remaining Novavax position as of Q2 2019 after selling out during the quarter.
SFE Investment Counsel sold 500 Novavax shares in Q2 2019, an estimated $6K.
SFE Investment Counsel first reported a position in Novavax in Q4 2018 and held it in 2 quarters.
SFE Investment Counsel's Novavax position peaked at $18K in Q4 2018.
81 funds tracked by Wall St. Rank held Novavax as of Q2 2019.

Based on SFE Investment Counsel's 13F filing for Q2 2019, filed 26 Jul 2019.